<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>29(3)</volume><submitter>Marshall SK</submitter><pubmed_abstract>This novel radiolabeled chitosan nanoparticle, facilitated with curcumin, increased doxorubicin cytotoxicity and radiosensitivity to MG-63 osteosarcoma cells in a three-dimensional model. Delivery of the anti-epidermal growth factor receptor (EGFR) targeted carboxymethyl chitosan nanoparticles, directly labeled with Na&lt;sup>131&lt;/sup>I (ICED-N), achieved deep tumor penetration in a three-dimensional model. Of three kinetic models, the Higuchi model more closely matched the experimental curve and release profiles. The anti-EGFR targeting resulted in a 513-fold greater targeting efficacy to MG-63 (EGFR+) cells than the control fibroblast (EGFR-) cells. The curcumin-enhanced ICED-N (4 × 0.925 MBq) fractionated-dose regime achieved an 18.3-fold increase in cell cytotoxicity compared to the single-dose (1 × 3.70 MBq) doxorubicin-loaded nanoparticle, and a 13.6-fold increase in cell cytotoxicity compared to the single-dose Na&lt;sup>131&lt;/sup>I nanoparticle. Moreover, the ICED-N fractionated dose increased cells in the G2/M phase 8.78-fold, indicating the cell cycle arrest in the G2/M phase is associated with DNA fragmentation, and the intracellular damage is unable to be repaired. Overall, the results indicate that the fractionated dose was more efficacious than a single dose, and curcumin substantially increased doxorubicin cytotoxicity and amplified osteosarcoma cell radiosensitivity to Na&lt;sup>131&lt;/sup>I.</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pagination>630</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10856476</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Cytotoxicity Enhancement in Osteosarcoma with Multifunctional I-131 Radiotherapeutic Nanoparticles: In Vitro Three-Dimensional Spheroid Model and Release Kinetics Modeling.</pubmed_title><pmcid>PMC10856476</pmcid><pubmed_authors>Taweesap M</pubmed_authors><pubmed_authors>Saelim B</pubmed_authors><pubmed_authors>Bumrungsin A</pubmed_authors><pubmed_authors>Kholo-Asae H</pubmed_authors><pubmed_authors>Marshall SK</pubmed_authors><pubmed_authors>Sangangam S</pubmed_authors><pubmed_authors>Wongtechanon I</pubmed_authors><pubmed_authors>Pachana V</pubmed_authors><pubmed_authors>Benlateh N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cytotoxicity Enhancement in Osteosarcoma with Multifunctional I-131 Radiotherapeutic Nanoparticles: In Vitro Three-Dimensional Spheroid Model and Release Kinetics Modeling.</name><description>This novel radiolabeled chitosan nanoparticle, facilitated with curcumin, increased doxorubicin cytotoxicity and radiosensitivity to MG-63 osteosarcoma cells in a three-dimensional model. Delivery of the anti-epidermal growth factor receptor (EGFR) targeted carboxymethyl chitosan nanoparticles, directly labeled with Na&lt;sup>131&lt;/sup>I (ICED-N), achieved deep tumor penetration in a three-dimensional model. Of three kinetic models, the Higuchi model more closely matched the experimental curve and release profiles. The anti-EGFR targeting resulted in a 513-fold greater targeting efficacy to MG-63 (EGFR+) cells than the control fibroblast (EGFR-) cells. The curcumin-enhanced ICED-N (4 × 0.925 MBq) fractionated-dose regime achieved an 18.3-fold increase in cell cytotoxicity compared to the single-dose (1 × 3.70 MBq) doxorubicin-loaded nanoparticle, and a 13.6-fold increase in cell cytotoxicity compared to the single-dose Na&lt;sup>131&lt;/sup>I nanoparticle. Moreover, the ICED-N fractionated dose increased cells in the G2/M phase 8.78-fold, indicating the cell cycle arrest in the G2/M phase is associated with DNA fragmentation, and the intracellular damage is unable to be repaired. Overall, the results indicate that the fractionated dose was more efficacious than a single dose, and curcumin substantially increased doxorubicin cytotoxicity and amplified osteosarcoma cell radiosensitivity to Na&lt;sup>131&lt;/sup>I.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2025-04-05T14:51:24.956Z</modification><creation>2025-04-05T14:51:24.956Z</creation></dates><accession>S-EPMC10856476</accession><cross_references><pubmed>38338373</pubmed><doi>10.3390/molecules29030630</doi></cross_references></HashMap>